Dual immunological blockade in the treatment of metastatic non-small cell lung cancer: reality and perspectives

Código QR

Dual immunological blockade in the treatment of metastatic non-small cell lung cancer: reality and perspectives

Nowadays immunotherapy is a crucial option in the treatment of non-small cell lung cancer. There are a lot of actual options of the first-line therapy for the patients with metastatic lung cancer, including dual immunological blockade of PD-1/PD-L1 and CTLA-4 pathways. This review is an attempt to c...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Denis I. Yudin, Konstantin K. Laktionov, Liudmila V. Laktionova, Valeriy V. Breder
Formato:	article
Lenguaje:	RU
Publicado:	IP Habib O.N. 2021
Materias:	dual immunotherapy metastatic lung cancer non-small cell lung cancer anti-pd1 anti-pd-l1 anti-ctla-4 anti-pd1/ctla-4 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/a92e51c914374d90b0dcf921ac158329
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

The Continuum of Thyroid Disorders Related to Immune Checkpoint Inhibitors: Still Many Pending Queries
por: Maria V. Deligiorgi, et al.
Publicado: (2021)

The phenomenon of pseudoprogression in cancer immunotherapy: is everything so unambiguous?
por: Vladislav O. Sarzhevskiy, et al.
Publicado: (2021)

Predictive Value of Baseline [18F]FDG PET/CT for Response to Systemic Therapy in Patients with Advanced Melanoma
por: Virginia Liberini, et al.
Publicado: (2021)

Hiding in the dark: pan-cancer characterization of expression and clinical relevance of CD40 to immune checkpoint blockade therapy
por: Chi Yan, et al.
Publicado: (2021)

Immunotherapeutic Advances for NSCLC
por: Massafra M, et al.
Publicado: (2021)

Immune-Related Adverse Events in PD-1 Treated Melanoma and Impact Upon Anti-Tumor Efficacy: A Real World Analysis
por: Melissa L. Bastacky, et al.
Publicado: (2021)

Immune Checkpoints Inhibitors and SRS/SBRT Synergy in Metastatic Non-Small-Cell Lung Cancer and Melanoma: A Systematic Review
por: María Rodríguez Plá, et al.
Publicado: (2021)

INFLUENCE OF ANTIBODIES AGAINST CTLA-4 AND PD-1 UPON QUANTITIES OF THEIR TARGET RECEPTORS
por: I. O. Chikileva, et al.
Publicado: (2019)

Encapsulated Checkpoint Blocker Before Chemotherapy: The Optimal Sequence of Anti-CTLA-4 and Doxil Combination Therapy
por: Alimohammadi R, et al.
Publicado: (2020)

Brief Report of Anti–Programmed Cell Death Protein-1 in Human Immunodeficiency Virus Setting: Relevant and Breaking Results in First-Line NSCLC Therapy
por: Lise Bertin, MD, et al.
Publicado: (2021)

Cure the Incurable? Recent Breakthroughs in Immune Checkpoint Blockade for Hepatocellular Carcinoma
por: Pei-Yi Chu, et al.
Publicado: (2021)

Cancer Cell Membrane Camouflaged Mesoporous Silica Nanoparticles Combined with Immune Checkpoint Blockade for Regulating Tumor Microenvironment and Enhancing Antitumor Therapy
por: Zhao P, et al.
Publicado: (2021)

Advances in Pancreatic Ductal Adenocarcinoma Treatment
por: Eric M. Anderson, et al.
Publicado: (2021)

CTLA-4 blockade in the treatment of colorectal cancer with microsatellite instability
por: Diana Russo, et al.
Publicado: (2021)

Treatment of Advanced Metastatic Melanoma
por: Pietro Quaglino, et al.
Publicado: (2021)

New targeted treatments for non-small-cell lung cancer – role of nivolumab
por: Zago G, et al.
Publicado: (2016)

Oral reactive capillary hemangiomas induced by SHR-1210 in the treatment of non-small cell lung cancer: a case report and literature review
por: Jinhan Zhou, et al.
Publicado: (2021)

Development of Indole Alkaloid-Type Dual Immune Checkpoint Inhibitors Against CTLA-4 and PD-L1 Based on Diversity-Enhanced Extracts
por: Yoshihide Suzuki, et al.
Publicado: (2021)

Myocarditis Induced by Immune Checkpoint Inhibitors: Mechanisms and Therapeutic Prospects
por: Zou W, et al.
Publicado: (2021)

Activity of PD-1 Inhibitor Combined With Anti-Angiogenic Therapy in Advanced Sarcoma: A Single-Center Retrospective Analysis
por: Yang You, et al.
Publicado: (2021)

Synergistic effects of AAGL and anti-PD-1 on hepatocellular carcinoma through lymphocyte recruitment to the liver
por: Xiangdong Ye, et al.
Publicado: (2021)

Use of nivolumab for colon cancer with Lynch syndrome
por: G. A. Khakimov, et al.
Publicado: (2020)

The commensal consortium of the gut microbiome is associated with favorable responses to anti-programmed death protein 1 (PD-1) therapy in thoracic neoplasms
por: Huihui Yin, et al.
Publicado: (2021)

Modern possibilities of immunotherapy in the treatment of extensive-stage small cell lung cancer: experience of durvalumab application. Case report
por: Albina S. Zhabina, et al.
Publicado: (2021)

Dl-3-N-Butylphthalide Presents Anti-Cancer Activity in Lung Cancer by Targeting PD-1/PD-L1 Signaling
por: Jiang Q, et al.
Publicado: (2021)

Anti-Tumor Necrosis Factor Receptor 2 Antibody Combined With Anti-PD-L1 Therapy Exerts Robust Antitumor Effects in Breast Cancer
por: Qiang Fu, et al.
Publicado: (2021)

Current Progress and Future Perspectives of Immune Checkpoint in Cancer and Infectious Diseases
por: Xin Cai, et al.
Publicado: (2021)

Anti-Angiogenic Agent Combined with Anti-PD-1 Immunotherapy Showed Activity in Patients With Classical Hodgkin Lymphoma Who Have Failed Immunotherapy: A Retrospective Case Report Study
por: Zheng Yan, et al.
Publicado: (2021)

The relationship between blood-based tumor mutation burden level and efficacy of PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis
por: He Ba, et al.
Publicado: (2021)

Case Report: Complete Response to Nivolumab in a Patient With Programmed Cell Death 1 Ligand 1-Positive and Multiple Gene-Driven Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma
por: Wen Dong, et al.
Publicado: (2021)

Tumor-immune profiling of CT-26 and Colon 26 syngeneic mouse models reveals mechanism of anti-PD-1 response
por: Yosuke Sato, et al.
Publicado: (2021)

High Inflammatory Tendency Induced by Malignant Stimulation Through Imbalance of CD28 and CTLA-4/PD-1 Contributes to Dopamine Neuron Injury
por: Dong L, et al.
Publicado: (2021)

Plasminogen Activating Inhibitor-1 Might Predict the Efficacy of Anti-PD1 Antibody in Advanced Melanoma Patients
por: Kentaro Ohuchi, et al.
Publicado: (2021)

Cost-Effectiveness of Ipilimumab Plus Anti-PD-1 Therapy Versus Ipilimumab Alone in Patients With Metastatic Melanoma Resistant to Anti-PD-(L)1 Monotherapy
por: Ye Peng, et al.
Publicado: (2021)

The use of atezolizumab in combination with chemotherapy in first-line of metastatic small cell lung cancer. Case report
por: Nikolai A. Ognerubov, et al.
Publicado: (2021)

Efficacy of PD‐1/PD‐L1 inhibitors in patients with non‐small cell lung cancer and brain metastases: A real‐world retrospective study in China
por: Jiamin Sheng, et al.
Publicado: (2021)

Immunotherapy-Related Cardiotoxicity Re-Emergence in Non-Small Cell Lung Cancer – A Case Report
por: Li Y, et al.
Publicado: (2021)

Anti-PD-1 Therapy—A Potential Treatment for Myocardial Metastasis From Nasopharyngeal Carcinoma: A Case Report
por: Xiaowan Tang, et al.
Publicado: (2021)

Profile of palbociclib in the treatment of metastatic breast cancer
por: Ehab M, et al.
Publicado: (2016)

Secretions from hypochlorous acid-treated tumor cells delivered in a melittin hydrogel potentiate cancer immunotherapy
por: Yuhan Zhou, et al.
Publicado: (2022)